LEO Pharma announced several key changes to its Executive Management team, marking a significant step forward in the company’s ongoing transformation journey. With strong progress made against strategic objectives, LEO Pharma is now focusing on long-term growth and the leadership profiles necessary to shape its future success.
As part of this strategic evolution, the company will separate its current Product Strategy and International Operations into two distinct functions. Consequently, Becki Morison, EVP of Product Strategy and International Operations, will be leaving LEO Pharma, effective end of June 2025.
Leadership Appointments to Drive Strategic Growth
Frederik Kier has been appointed EVP, International Operations, and will join LEO Pharma on June 1, 2025. Frederik comes from Novo Nordisk, where he most recently served as Senior Vice President of the Global Obesity Unit. His extensive global experience includes senior leadership roles across key international regions such as Northwest Europe and AAMEO (Africa, Asia, Middle East, and Oceania).
Lisa Elliott, currently Vice President, Global Assets and Payer Strategy at LEO Pharma, will assume the role of interim Head of Global Product Strategy. The company has initiated an external search to appoint a permanent leader for the newly established Global Product Strategy function.
Changes in Development Leadership
Kreesten Meldgaard Madsen, EVP of Development, will also be stepping down from his role. A search is underway to identify the right long-term leader for the Development organization.
In the interim, Dr. Mark Levick will step in as EVP of Development, effective immediately. Mark is currently a member of LEO Pharma’s Board of Directors and Chair of its Innovation Committee. A Doctor of Medicine with a PhD in Vaccine Development, Mark brings deep R&D and global drug development experience from leadership roles at major pharmaceutical firms, including his role as Global Head of Development at Novartis. Kreesten will support a smooth transition and depart by the end of June 2025.
New HR Executive Appointment
LEO Pharma has also appointed a new EVP, Head of Global People and Corporate Affairs (GPCA), who will join the company on July 1, 2025. The individual’s name will be announced in coordination with their current employer. Michael Meyer, interim EVP of GPCA, will step down following the transition.
A Message from the CEO
“We are now at a point on our journey that requires us to look further ahead, focusing on the leadership profiles needed to shape our future,” said Christophe Bourdon, CEO of LEO Pharma. “We must sharpen our commercial setup and further strengthen our development organization to meet our ambitious goals. These changes are pivotal to our strategy of fully realizing the potential of our innovative product portfolio, launching it globally and expanding its indications.”
Christophe Bourdon added: “I would like to extend my sincere gratitude to Becki and Kreesten for their outstanding leadership during a time of significant transformation at LEO Pharma. Their contributions have been instrumental in bringing us to where we are today.”
Comments powered by CComment